Spruce Biosciences, Inc. (SPRB)
| Market Cap | 152.68M +2,620.3% |
| Revenue (ttm) | n/a |
| Net Income | -38.97M |
| EPS | -50.83 |
| Shares Out | 2.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,016 |
| Open | 57.50 |
| Previous Close | 56.57 |
| Day's Range | 56.20 - 57.50 |
| 52-Week Range | 4.35 - 240.00 |
| Beta | 3.31 |
| Analysts | Strong Buy |
| Price Target | 190.60 (+237.35%) |
| Earnings Date | May 19, 2026 |
About SPRB
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sle... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SPRB stock is "Strong Buy." The 12-month stock price target is $190.6, which is an increase of 237.35% from the latest price.
News
Spruce Biosciences appoints Brian Walls as VP, market access
Spruce Biosciences (SPRB) announced the appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations. Most recently, Walls served as Vice Pr...
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Craig-Hallum bullish on Spruce Biosciences, initiates with a Buy
AS previously reported, Craig-Hallum initiated coverage of Spruce Biosciences (SPRB) with a Buy rating and $140 price target. The firm notes the company’s TA-ERT is an enzyme replacement therapy for
Spruce Biosciences initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Albert Lowe initiated coverage of Spruce Biosciences (SPRB) with a Buy rating and $140 price target
Spruce Biosciences 1.15M share Spot Secondary priced at $50.00
Leerink, Guggenheim and Oppenheimer acted as joint book running managers for the offering.
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel the...
Spruce Biosciences down 13% at $60.50 after equity offering announcement
16:48 EDT Spruce Biosciences (SPRB) down 13% at $60.50 after equity offering announcement
Spruce Biosciences announces common stock offering, no amount given
Spruce Biosciences (SPRB) announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu
Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences”) (NASDAQ: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel the...
Spruce Biosciences Transcript: The Citizens Life Sciences Conference 2026
Lead asset for MPS IIIB shows robust clinical benefit and safety, with regulatory progress supported by FDA engagement and a Q4 BLA submission planned. Commercial strategy targets a rare disease market with strong patient advocacy, and financial runway extends into 2027.
Spruce Biosciences price target lowered to $170 from $180 at Citizens
Citizens lowered the firm’s price target on Spruce Biosciences (SPRB) to $170 from $180 and keeps an Outperform rating on the shares. The firm continues to like Tralesinidase Alfa Enzyme
Spruce Biosciences Transcript: Leerink Global Healthcare Conference 2026
FDA engagement has been positive, supporting accelerated approval based on robust biomarker and clinical data, with BLA submission planned for Q4. Commercial and manufacturing strategies are advancing, and financial runway is expected into 2027, with additional funding options available.
Spruce Biosciences appoints Dale Hooks as chief commercial officer
Spruce Biosciences (SPRB) announced the appointment of Dale Hooks as chief commercial officer. Hooks joins the company with nearly 35 years of pharmaceutical marketing and sales experience, including ...
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences to Present at Upcoming Investor Conferences in March
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
TA-ERT is advancing toward FDA approval for MPS IIIB, with strong clinical data and a BLA submission planned for late 2024. The therapy shows durable efficacy, a favorable safety profile, and significant market potential, with commercialization strategies focused on specialized centers and global partnerships.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Spruce Biosciences (SPRB), 213.3% surge in interest Pipel...
Spruce Biosciences price target lowered to $200 from $220 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Spruce Biosciences (SPRB) to $200 from $220 and keeps a Buy rating on the shares. The firm says the
Spruce Biosciences provides update on Type B tralesinidase meetings with FDA
Spruce Biosciences (SPRB) announced the successful completion of Type B meetings with FDA or the Agency regarding its planned upcoming biologics license application submission for tralesinidase alfa e...
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...